R3 Vascular's Breakthrough in the Medical Device Landscape
May 21, 2024, 3:34 pm
Location: United States, California, Livermore
Employees: 1-10
Founded date: 2019
Total raised: $87M
R3 Vascular, a pioneering medical device company based in Mountain View, California, has recently captured the attention of the industry with its groundbreaking bioresorbable scaffold for peripheral artery disease. Securing an impressive $87 million in Series B financing and appointing Christopher M. Owens as the new President and CEO, the company is poised for a significant leap forward in the medical technology sector.
The substantial funding injection will play a crucial role in supporting pivotal clinical trials for R3's bioresorbable, drug-eluting stent, known as MAGNITUDE®. This innovative stent is specifically designed to address severe below-the-knee cases of peripheral artery disease, offering a promising alternative to traditional treatment methods such as balloon angioplasty. With the potential to challenge established players like Abbott, R3 Vascular's technology represents a significant advancement in vascular care.
Led by the newly appointed President and CEO, Christopher M. Owens, R3 Vascular is on a trajectory to revolutionize the field of vascular medicine with its cutting-edge solutions. The company's focus on developing fully bioresorbable sirolimus-coated vascular scaffolds sets it apart in the industry, combining the supportive properties of a scaffold with the anti-inflammatory benefits of sirolimus. As these scaffolds gradually dissolve over time, they promote vessel healing, offering a unique approach to treating peripheral artery disease.
R3 Vascular's novel bioresorbable scaffolds are crafted from an ultra-high molecular weight polylactic acid polymer, a material that, when combined with the company's proprietary processing techniques, results in thinner, stronger, and more flexible scaffolds, even at longer lengths. This innovative approach to medical device design showcases R3 Vascular's commitment to pushing the boundaries of what is possible in vascular care.
With the support of the recent funding round, R3 Vascular is well-positioned to advance its technology through additional research and development, global regulatory submissions, scaling up manufacturing processes, and initial commercialization efforts. The company's dedication to innovation and patient care underscores its potential to make a lasting impact on the medical device landscape.
In conclusion, R3 Vascular's rise in the medical device industry signals a new era of possibilities for treating peripheral artery disease. With a strong leadership team, innovative technology, and significant financial backing, the company is poised to shape the future of vascular medicine and improve patient outcomes worldwide.
The substantial funding injection will play a crucial role in supporting pivotal clinical trials for R3's bioresorbable, drug-eluting stent, known as MAGNITUDE®. This innovative stent is specifically designed to address severe below-the-knee cases of peripheral artery disease, offering a promising alternative to traditional treatment methods such as balloon angioplasty. With the potential to challenge established players like Abbott, R3 Vascular's technology represents a significant advancement in vascular care.
Led by the newly appointed President and CEO, Christopher M. Owens, R3 Vascular is on a trajectory to revolutionize the field of vascular medicine with its cutting-edge solutions. The company's focus on developing fully bioresorbable sirolimus-coated vascular scaffolds sets it apart in the industry, combining the supportive properties of a scaffold with the anti-inflammatory benefits of sirolimus. As these scaffolds gradually dissolve over time, they promote vessel healing, offering a unique approach to treating peripheral artery disease.
R3 Vascular's novel bioresorbable scaffolds are crafted from an ultra-high molecular weight polylactic acid polymer, a material that, when combined with the company's proprietary processing techniques, results in thinner, stronger, and more flexible scaffolds, even at longer lengths. This innovative approach to medical device design showcases R3 Vascular's commitment to pushing the boundaries of what is possible in vascular care.
With the support of the recent funding round, R3 Vascular is well-positioned to advance its technology through additional research and development, global regulatory submissions, scaling up manufacturing processes, and initial commercialization efforts. The company's dedication to innovation and patient care underscores its potential to make a lasting impact on the medical device landscape.
In conclusion, R3 Vascular's rise in the medical device industry signals a new era of possibilities for treating peripheral artery disease. With a strong leadership team, innovative technology, and significant financial backing, the company is poised to shape the future of vascular medicine and improve patient outcomes worldwide.